Orion (OEC)

NYSE Markedet er åpent

Orion S.A. is a global producer of carbon black, a finely divided form of carbon used to change the strength, durability, conductivity, colour, and processing characteristics of industrial materials. The company supplies customers across automotive, tire, coatings, plastics, printing, battery, and other specialty markets, making it part of the chemical supply chain behind many everyday and industrial products.

Orion reports its business through two main segments: Rubber Carbon Black and Specialty Carbon Black. Rubber Carbon Black is the larger revenue contributor and is primarily used to reinforce tires and mechanical rubber goods, where it helps improve wear resistance, tensile strength, and overall performance. Demand in this segment is closely tied to tire production, vehicle use, replacement tire cycles, and broader industrial activity.

The Specialty Carbon Black segment serves higher-value applications where carbon black functions as a pigment or performance additive. These products are used in coatings, inks, polymers, cables, conductive compounds, and other applications that require specific colour, electrical, or technical properties. Specialty grades can be more customized than standard rubber grades, giving Orion exposure to markets where material performance is a key purchasing factor.

The company operates internationally, with a significant revenue base in Europe and particularly Germany, according to its reported geographic mix. Orion’s position is shaped by manufacturing scale, technical know-how, customer qualification requirements, and the need to meet environmental and quality standards in a heavily regulated chemicals industry.

7.18 USD
−0.08 (-1.17%)

Sist oppdatert

Markedsverdi
410.51M
P/E-tall
P/FCF-tall
11.7
P/S-tall
0.23
Selskapsverdi
1.37B
Sektor
Bransje
Adresse
1700 CITY PLAZA DRIVE, SUITE 300, SPRING, TX, 77389
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–maaliskuu 2026

23. apr. 2026, 11:00 A.M.
GlobeNewswire Inc.

Gabelli Hosts 17th Annual Specialty Chemicals Symposium

24. feb. 2026, 14:00 P.M.
GlobeNewswire Inc.

Orion Group Interim Report January–September 2025

28. okt. 2025, 11:00 A.M.
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–syyskuu 2025

28. okt. 2025, 11:00 A.M.
GlobeNewswire Inc.

Orion-konsernin puolivuosikatsaus tammi–kesäkuu 2025

18. juli 2025, 11:00 A.M.
GlobeNewswire Inc.

Sisäpiiritieto: Orion parantaa näkymäarviota vuodelle 2025

09. juli 2025, 12:00 P.M.
GlobeNewswire Inc.

Orion ja Glykos laajentavat tutkimusyhteistyö- ja lisenssisopimustaan seuraavan sukupolven vasta-ainekonjugaattien kehittämiseksi

17. juni 2025, 08:00 A.M.
GlobeNewswire Inc.

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

17. juni 2025, 08:00 A.M.
GlobeNewswire Inc.

Orionin yhteistyökumppani MSD laajentaa opevesostaatin kliinistä kehitysohjelmaa naisten syöpiin

21. mai 2025, 06:30 A.M.
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–maaliskuu 2025

23. apr. 2025, 11:00 A.M.
GlobeNewswire Inc.

Lääketeollisuus luovutti hallitukselle arvolupauksen: miljarditason investoinnit vuoteen 2030 mennessä

21. mars 2025, 12:00 P.M.
GlobeNewswire Inc.

Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide

07. jan. 2025, 08:00 A.M.
GlobeNewswire Inc.

Orionin yhteistyökumppani Bayer hakee Kiinassa kolmatta indikaatiota darolutamidille

07. jan. 2025, 08:00 A.M.
GlobeNewswire Inc.

Orion ja Abilita Therapeutics sopivat tutkimusyhteistyöstä ja lisenssisopimusoptiosta innovatiivisten vasta-ainehoitojen kehittämiseksi

18. des. 2024, 16:00 P.M.
GlobeNewswire Inc.

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics

18. des. 2024, 16:00 P.M.
GlobeNewswire Inc.

Sisäpiiritieto: Orion lopettaa ODM-111-kehitysohjelman perustuen molekyylin liian kapeaan terapeuttiseen ikkunaan

24. okt. 2024, 18:50 P.M.
GlobeNewswire Inc.

Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule

24. okt. 2024, 18:50 P.M.
GlobeNewswire Inc.

Orionin yhteistyökumppani Bayer hakee EU:ssa kolmatta indikaatiota darolutamidille

14. okt. 2024, 10:00 A.M.
GlobeNewswire Inc.

Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

14. okt. 2024, 10:00 A.M.
GlobeNewswire Inc.

Darolutamidi yhdessä ADT-hoidon kanssa pienensi merkitsevästi (46 prosentilla) syövän etenemisen tai kuoleman riskiä verrattuna lumelääkkeen ja ADT:n yhdistelmään levinnyttä hormonisensitiivistä eturauhassyöpää sairastavilla potilailla

16. sep. 2024, 10:30 A.M.
Markedsverdi
410.51M
Selskapsverdi
1.37B
P/E-tall
P/B-tall
1.08
P/S-tall
0.23
EV / EBITDA-forhold
6.49
EV / omsetning
0.77
Resultat per aksje
-1.58
Utbytterente
1.14%
P/FCF-tall
11.7
P/CF-tall
2.02
Fri kontantstrøm
35.1M
Avkastning på egenkapital
-23.48%
Avkastning på eiendeler
-4.61%
Gjeld / egenkapital
2.67
Likviditetsgrad I
1
Likviditetsgrad II
0.62
Kontanter
0.08
Snittvolum
460.37K
Fundamentalpris (snapshot)
7.28

Resultatregnskap

Post 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Omsetning 459.5M 411.7M 450.9M 466.4M 477.7M
Bruttofortjeneste 79.2M 77.7M 85.6M 98.4M 98.1M
Driftsresultat 11.4M 13.5M -52.3M 32.1M 31.2M
Driftsresultat før avskrivninger (EBITDA) 44.1M 41.3M 62.2M 64.1M 62.7M
Nettoresultat -9.9M -21.1M -67.1M 9M 9.1M
Grunnleggende EPS -0.18 -0.37 -1.2 0.16 0.16
Utvanet EPS -0.18 -0.37 -1.2 0.16 0.16

Balanse

Post 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Sum eiendeler 1.93B 1.91B 1.96B 2.02B 1.97B
Sum gjeld 1.55B 1.52B 1.56B 1.56B 1.5B
Egenkapital 379.5M 384.6M 401.8M 466.5M 466.1M
Kontanter og ekvivalenter 50.5M 60.7M 51.3M 42.6M 37.5M
Omløpsmidler 661.5M 643.8M 683.5M 682.5M 688.6M
Kortsiktig gjeld 659.7M 626.4M 635.3M 620.8M 601.9M

Kontantstrøm

Post 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Kontantstrøm fra drift -12.4M 92.9M 68.8M 53.7M 400K
Kontantstrøm fra investeringer -36.1M -48.7M -40.9M -42.2M -29.2M
Kontantstrøm fra finansiering 39.6M -35.7M -19.5M -7.8M 21.8M
Endring i kontanter -8.9M 8.5M 8.4M 3.7M -7M
Type Rapport Dato Lenke
edgar index 8-K — Orion S.A. Vis rapport
edgar index 10-Q — Orion S.A. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 4 — Orion S.A. Vis rapport
edgar index 4 — Orion S.A. Vis rapport
edgar index 4 — Orion S.A. Vis rapport
edgar index 4 — Orion S.A. Vis rapport
edgar index 4 — Orion S.A. Vis rapport
form 4 Form 4 — Niewiem Sandra Vis rapport
form 4 Form 4 — Painter Corning F. Vis rapport
form 4 Form 4 — Puckett Jonathan A. Vis rapport
form 4 Form 4 — Quinones Carlos Vis rapport
form 4 Form 4 — Riveros Pedro Vis rapport
edgar index ARS — Orion S.A. Vis rapport
edgar index DEF 14A — Orion S.A. Vis rapport
edgar index 8-K — Orion S.A. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index PRE 14A — Orion S.A. Vis rapport
edgar index 8-K — Orion S.A. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — Orion S.A. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — Orion S.A. Vis rapport
edgar index SCHEDULE 13G — Orion S.A. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 4 — Orion S.A. Vis rapport
edgar index 4 — Orion S.A. Vis rapport
edgar index 4 — Orion S.A. Vis rapport
edgar index 4 — Orion S.A. Vis rapport
form 4 Form 4 — Niewiem Sandra Vis rapport
form 4 Form 4 — Niewiem Sandra Vis rapport
form 4 Form 4 — Niewiem Sandra Vis rapport
form 4 Form 4 — Painter Corning F. Vis rapport
form 4 Form 4 — Painter Corning F. Vis rapport
form 4 Form 4 — Painter Corning F. Vis rapport
form 4 Form 4 — Quinones Carlos Vis rapport
form 4 Form 4 — Quinones Carlos Vis rapport
form 4 Form 4 — Quinones Carlos Vis rapport
form 4 Form 4 — Riveros Pedro Vis rapport
form 4 Form 4 — Riveros Pedro Vis rapport
form 4 Form 4 — Riveros Pedro Vis rapport
edgar index 8-K — Orion S.A. Vis rapport
edgar index 10-K — Orion S.A. Vis rapport
eight k text 8-K — 8-K Vis rapport
ten k section 10-K — business Vis rapport
ten k section 10-K — mda Vis rapport
ten k section 10-K — risk_factors Vis rapport
edgar index 4 — Orion S.A. Vis rapport
form 4 Form 4 — Puckett Jonathan A. Vis rapport
edgar index 3 — Orion S.A. Vis rapport
edgar index 8-K — Orion S.A. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — Orion S.A. Vis rapport
edgar index 10-Q — Orion S.A. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — Orion S.A. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — Orion S.A. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — Orion S.A. Vis rapport
edgar index 8-K — Orion S.A. Vis rapport
edgar index 10-Q — Orion S.A. Vis rapport
edgar index SCHEDULE 13G/A — Orion S.A. Vis rapport
edgar index 8-K — Orion S.A. Vis rapport
edgar index SCHEDULE 13G/A — Orion S.A. Vis rapport
edgar index 3 — Orion S.A. Vis rapport
edgar index 4 — Orion S.A. Vis rapport
edgar index 4 — Orion S.A. Vis rapport
edgar index 4 — Orion S.A. Vis rapport
edgar index 4 — Orion S.A. Vis rapport
edgar index 4 — Orion S.A. Vis rapport
edgar index 4 — Orion S.A. Vis rapport
edgar index 4 — Orion S.A. Vis rapport
edgar index 4 — Orion S.A. Vis rapport
form 4 Form 4 — GALVIN KERRY A Vis rapport